Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its new injectable facility located in Nagpur, India. The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022.

"We are very happy to have received the EIR for our Nagpur injectable facility from the US FDA," said Nilesh Gupta, Managing Director, Lupin. "Our state-of-the-art injectable facility at Nagpur is designed to the highest quality standards and adheres to international regulations with advanced technology and equipment. We are committed to bringing an important portfolio of injectables addressing unmet needs from the facility."

Shares of Lupin Limited was last trading in BSE at Rs. 682.35 as compared to the previous close of Rs. 668.70. The total number of shares traded during the day was 27922 in over 1093 trades.

The stock hit an intraday high of Rs. 686.30 and intraday low of 669.00. The net turnover during the day was Rs. 19000304.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 EIR USFDA InjectableFacility Nagpur